May 2024

1 May 2024

Require Senior Research Scientist at o2h group

Responsible for smoother operation of NMR instruments, shift planning and execution to achieve benchmark productivity month on month basis. Responsible for planning, prioritizing and executing work responsibilities in order to meet deadlines.

1 May 2024

EMA recommends marketing authorisation for Truqap

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Truqap, intended for the treatment of locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations.

1 May 2024

IIT Bombay unveils 10x GMP facility for pharma companies

IIT Bombay unveils the nations first of its kind GMP facility at any academic institution The 10X GMP Facility at IIT Bombay is the first-of- its- kind in India and will help to manufacture products for human trials. This facility will encourage researchers to manufacture breakthrough products in healthcare which are 10 times cheaper or better or faster than anything currently available.

1 May 2024

Lilly Q1 2024 increased by 26 percent driven by Mounjaro, Zepbound, Verzenio and Jardiance

In Q1 2024, worldwide revenue was USD 8.77 billion, an increase of 26 percent compared with Q1 2023, driven by increases of 16 percent in volume and 10 percent due to higher realized prices. The volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio and Jardiance, partially offset by declines in Trulicity.

1 May 2024

Sanofi has launched GLP-1 drug in India

Soliqua is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.

1 May 2024

Denmark to restrict Ozempic and other GLP-1 drugs for Diabetes

Denmark rationalised cheaper diabetic medicines and restricted GLP-1 analogues. The so-called GLP-1 analogues, which include is known under the product names Ozempic, Trulicity, Rybelsus and Victoza, is significantly more expensive than other types of diabetes medication (so-called DPP-4 inhibitors, SGLT-2 inhibitors, beta-cell stimulants and metformin)

1 May 2024

Caprylhydroxamic acid (KOPSYM)- Dual active for Cosmetics

Caprylhydroxamic acid is a synthetic chelating agent that helps protect cosmetic formulas from destabilizing metal ions. It also works as a preservative, having the ability to prevent mold growth in water-based formulas. This ingredient has great flexibility since it works in all types of cosmetic formulas, including waterless (anhydrous) and its efficacy is not pH-dependent.